Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.
Cell
; 187(13): 3373-3389.e16, 2024 Jun 20.
Article
en En
| MEDLINE
| ID: mdl-38906102
ABSTRACT
The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint inhibitors (ICIs). However, there is no consensus definition of detrimental dysbiosis. Based on metagenomics (MG) sequencing of 245 non-small cell lung cancer (NSCLC) patient feces, we constructed species-level co-abundance networks that were clustered into species-interacting groups (SIGs) correlating with overall survival. Thirty-seven and forty-five MG species (MGSs) were associated with resistance (SIG1) and response (SIG2) to ICIs, respectively. When combined with the quantification of Akkermansia species, this procedure allowed a person-based calculation of a topological score (TOPOSCORE) that was validated in an additional 254 NSCLC patients and in 216 genitourinary cancer patients. Finally, this TOPOSCORE was translated into a 21-bacterial probe set-based qPCR scoring that was validated in a prospective cohort of NSCLC patients as well as in colorectal and melanoma patients. This approach could represent a dynamic diagnosis tool for intestinal dysbiosis to guide personalized microbiota-centered interventions.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Microbioma Gastrointestinal
/
Inmunoterapia
/
Neoplasias Pulmonares
/
Neoplasias
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Cell
Año:
2024
Tipo del documento:
Article